• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CFO O'Toole David D

    1/22/25 4:30:05 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    O'Toole David D

    (Last) (First) (Middle)
    28159 AVENUE STANFORD
    SUITE 220 - AVITA MEDICAL

    (Street)
    VALENCIA CA 91355

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AVITA Medical, Inc. [ RCEL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    01/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy) $8.73 01/21/2025 A 150,000 (1) 01/21/2034 Common Stock 150,000 $0 150,000 D
    Explanation of Responses:
    1. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.
    David O'Toole 01/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Financials

    Live finance-specific insights

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024, the FDA granted 510(k) clearance for Cohealyx™, an AVITA Medical-branded collagen-based dermal matrixOn December 23, 2024, the FDA approved RECELL GO® miniOn February 13, 2025, amended the credit

      2/13/25 4:01:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      2/13/24 4:58:57 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      1/26/24 4:23:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

      SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

      2/9/23 11:07:47 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

      VALENCIA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time. The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound Care Showcase will provide an overview of AVITA Medical's comprehensive approach to acute wound care. Attendees joining the webcast will gain insights into the company's product portfolio, includi

      4/24/25 9:00:00 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer

      VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public

      6/15/23 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Appoints New Non-Executive Member to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He

      3/23/23 4:30:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avita Medical Inc.

      10-Q - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:15:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:05:17 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Avita Medical Inc.

      DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)

      4/22/25 4:30:18 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Avita Medical with a new price target

      D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

      12/24/24 7:10:27 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical downgraded by BTIG Research

      BTIG Research downgraded Avita Medical from Buy to Neutral

      4/11/24 7:58:22 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Avita Medical with a new price target

      Cantor Fitzgerald initiated coverage of Avita Medical with a rating of Overweight and set a new price target of $23.00

      6/27/23 7:26:40 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care